Valuation: Evotec

Market Cap 915M 1.05B 843M 783M 1.49B 99.7B 1.51B 10.09B 3.93B 48.94B 3.93B 3.84B 170B P/E 2026 *
-7.25x
P/E 2027 * -26.4x
Enterprise Value 930M 1.06B 856M 795M 1.51B 101B 1.53B 10.25B 3.99B 49.7B 3.99B 3.9B 172B EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.2x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 43 2022-06-21
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 1.05B
+1.08%+8.57%+3.61%+9.34% 49.92B
+0.40%-1.37%+401.69%+625.15% 40.23B
-0.52%+6.57%+25.41%-5.37% 34.55B
+3.97%+6.71%+26.06%+63.36% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-2.40%+1.60% - - 17.05B
+1.34%+5.68%+75.77%+141.51% 15.92B
-0.95%+0.76%+12.92%+21.59% 13.86B
+1.69%+3.09%+93.44%+99.19% 13.52B
Average +0.88%+5.72%+80.33%+123.37% 27.3B
Weighted average by Cap. +0.27%+6.43%+91.13%+141.32%

Financials

2026 *2027 *
Net sales 738M 842M 679M 631M 1.2B 80.34B 1.21B 8.13B 3.16B 39.43B 3.16B 3.09B 137B 818M 934M 753M 699M 1.33B 89.07B 1.35B 9.02B 3.51B 43.72B 3.51B 3.43B 152B
Net income -113M -129M -104M -96.8M -184M -12.33B -186M -1.25B -486M -6.05B -486M -475M -20.99B -30.42M -34.74M -28.02M -26.01M -49.39M -3.31B -50.06M -335M -131M -1.63B -130M -128M -5.64B
Net Debt 14.3M 16.33M 13.17M 12.23M 23.22M 1.56B 23.53M 158M 61.36M 765M 61.32M 59.97M 2.65B 69.32M 79.16M 63.85M 59.27M 113M 7.55B 114M 764M 297M 3.71B 297M 291M 12.85B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.150EUR
Average target price
6.871EUR
Spread / Average Target
+33.43%

Quarterly revenue - Rate of surprise